0000000000352507

AUTHOR

Vera Gorbunova

showing 3 related works from this author

Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.

2013

4021 Background: In the EXPAND study adding cetuximab to first-line capecitabine and cisplatin chemotherapy (CT) failed to improve clinical outcome in patients (pts) with advanced gastric or gastroesophageal junction cancer. This analysis assessed treatment outcome according to tumor HER2 status (a pre-defined subgroup) and EGFR expression in EXPAND study pts. Methods: Tumor HER2 status was determined primarily by immunohistochemistry (IHC), HER2 +ve tumors were IHC 3+ or IHC 2+ and fluorescence in situ hybridization (FISH) +ve. EGFR expression was assessed by IHC. A continuous scoring system (scale of 0–300) was used to determine the level of EGFR expression. Biomarker status was correlat…

OncologyCisplatinCancer ResearchChemotherapymedicine.medical_specialtyCetuximabbusiness.industrymedicine.medical_treatmentAdvanced gastric cancerEgfr expressionCapecitabineOncologyGastro-Internal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival…

2015

Summary Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Methods Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only). We planned analyses of mature overall sur…

AdultMalemedicine.medical_specialtyGuanineLung NeoplasmsAfatinibPopulationMedizinPemetrexedNeutropeniaAdenocarcinomaAfatinibGastroenterologyDeoxycytidineGlutamatesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansRociletinibeducationLung cancerSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle Agedmedicine.diseasePrognosisGemcitabineSurgeryErbB ReceptorsSurvival RatePemetrexedOncologyMutationQuinazolinesFemaleCisplatinbusinessmedicine.drugFollow-Up StudiesThe Lancet. Oncology
researchProduct

Genome-wide adaptive complexes to underground stresses in blind mole rats Spalax

2014

The blind mole rat (BMR), Spalax galili, is an excellent model for studying mammalian adaptation to life underground and medical applications. The BMR spends its entire life underground, protecting itself from predators and climatic fluctuations while challenging it with multiple stressors such as darkness, hypoxia, hypercapnia, energetics and high pathonecity. Here we sequence and analyse the BMR genome and transcriptome, highlighting the possible genomic adaptive responses to the underground stressors. Our results show high rates of RNA/DNA editing, reduced chromosome rearrangements, an over-representation of short interspersed elements (SINEs) probably linked to hypoxia tolerance, degene…

SpalaxGeneral Physics and AstronomyZoologyBiologyGenomeGeneral Biochemistry Genetics and Molecular BiologyEvolution MolecularHypercapniaTranscriptome03 medical and health sciences0302 clinical medicineStress PhysiologicalMoleAnimalsHypoxiaSpalax galiliShort Interspersed Nucleotide Elements030304 developmental biologyHigh rate0303 health sciencesGenomeMultidisciplinaryGene Expression ProfilingGeneral ChemistryDarknessbiology.organism_classificationAdaptation PhysiologicalEvolutionary biologySpalaxRNA EditingAdaptationTranscriptome030217 neurology & neurosurgeryNature Communications
researchProduct